GlassScriptPhysician profile
Davy L Figueroa
NPI 1780794735
$11,641.57
in general payments reported to CMS, 2019-2025
30 companies · $1,267 in 2025
The $1,267 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,174 · 2020: $172 · 2021: $1,855 · 2022: $1,560 · 2023: $1,395 · 2024: $2,219 · 2025: $1,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,880.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,124.16 | 2019-2025 | Breztri, Airsupra, Andexxa |
| Gilead Sciences, INC. | $1,620.20 | 2019-2025 | Epclusa, Vemlidy |
| Glaxosmithkline, LLC. | $967.54 | 2019-2025 | Arexvy, Nucala |
| Abbvie INC. | $831.49 | 2019-2024 | |
| Novo Nordisk INC | $804.60 | 2019-2025 | Ozempic |
| Janssen Pharmaceuticals, INC | $707.10 | 2019-2024 | Xarelto |
| Amgen INC. | $614.38 | 2021-2024 | Tepezza, Repatha |
| Lilly USA, LLC | $541.13 | 2019-2025 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $487.68 | 2019-2023 | Austedo, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.35 | 2019-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $253.16 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $226.48 | 2022-2023 | Nuzyra |
| Optinose US, INC. | $213.88 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $166.30 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $142.23 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $134.80 | 2021-2023 | |
| Madrigal Pharmaceuticals | $134.40 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $124.99 | 2021 | |
| La Jolla Pharmaceutical Company | $124.99 | 2023 | Xerava |
| Shionogi INC | $124.43 | 2024 | Fetroja |
| Merck Sharp & Dohme LLC | $101.45 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.03 | 2019 | |
| Allergan, INC. | $97.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $96.12 | 2019 | |
| Lantheus Medical Imaging, INC. | $95.86 | 2019 | |
| Smith+Nephew, INC. | $94.77 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $90.06 | 2019 | |
| Pfizer INC. | $18.98 | 2019 | |
| Mylan Specialty L.P. | $16.91 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davy Figueroa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.